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A B S T R A C T
The growing understanding of the molecular mechanisms underlying epithelial-to-mesenchymal
transition (EMT) may represent a potential source of clinical markers. Despite EMT drivers have not yet
emerged as candidate markers in the clinical setting, their association with established clinical markers
may improve their speciﬁcity and sensitivity. Mass spectrometry-based platforms allow analyzing
multiple samples for the expression of EMT candidate markers, and may help to diagnose diseases or
monitor treatment efﬁciently. This review highlights proteomic approaches applied to elucidate the
differences between epithelial and mesenchymal tumors and describes how these can be used for target
discovery and validation.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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A major concern in the management of tumor patients is the
presence of metastatic cells in distant organs. Activation of the
epithelial-to-mesenchymal transition (EMT) program is commonly
observed in human cancers and is closely related to tumor
progression and resistance to standard chemotherapeutic drugs
and targeted agents. This model proposes morphological changes
in the structural organization of epithelial cells, with epithelial
polarized cells that lose their apical-basal organization and acquire* Corresponding author at: University of Salento, Strada Prov. Monteroni Km. 7,
Lecce 73100, Italy.
E-mail addresses: danielevergara@libero.it (V. Daniele),
michele.mafﬁa@unisalento.it (M. Michele).
http://dx.doi.org/10.1016/j.euprot.2016.01.003
2212-9685/ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteom
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a ﬁbroblast-like shape, as well as fundamental changes at different
genetic and epigenetic levels that can initiate and sustain the
process [1].
EMT is a dynamic process that does not occur homogenously
across the whole tumor. This is supported by the observation that
inside the tumor mass, cells with mesenchymal features reside
predominantly at the invasive front at the tumor-stroma interface
[2]. Within a tumor, epithelial and mesenchymal cells coexist and
cooperate, by direct cell-cell interactions or by diffusible factors,
allowing epithelial cells to undergo EMT and increase their ability
to locally invade into the surrounding tissues and intravasate into
the blood vessels, initiating their spreading to distant organs [3].
After disseminating through the circulation, circulating tumor
cells (CTCs) maintain the expression of mesenchymal markers and
a molecular proﬁling of these cells may be carried out to predict
disease progression [4,5]. Although antibodies against epithelialics Association (EuPA). This is an open access article under the CC BY-NC-ND license
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CK-19) have been widely used to isolate CTCs, more recent and
sensitive methods that include a cocktail of antibodies against
mesenchymal markers have been developed [6,8]. This approach
demonstrated clinical validity by its ability to predict more
accurately breast cancer patients with a worse prognosis than
the evaluation of epithelial antigens [5]. This was also conﬁrmed in
other studies where a higher numbers of mesenchymal CTCs were
identiﬁed in patients in the metastatic stage of the disease in a
variety of tumor types [6]. For this reason, multiple devices were
developed and functionalized not only with epithelial markers but
also with mesenchymal markers combined with cancer-associated
antigens, such as HER2 (EGFR2/ERBB2), and epithelial growth
factor receptor (EGFR) [4]. Moreover, together with the detection
of commonly used EMT molecules, there is also a need to identify
new speciﬁc CTCs markers. To address this issue, protein-based
technologies that rely on speciﬁc markers that are not down-
regulated during EMT and absent in blood cells were also described
and validated [9].
At present, one of the key questions is whether epithelial or
mesenchymal detection methods are able to capture the entire
spectrum of CTCs. It should be noted that the detection of CTCs
based on the expression of a speciﬁc set of markers should require
an assumption about the nature of these cells, and considering the
heterogeneity of CTCs, this cannot be easily predicted. As the EMT
features of CTCs can evolve in a spectrum of different phenotypic
phases during disease progression or treatment, current efforts to
characterise simultaneously CTCs with epithelial and mesenchy-
mal features might be the key not only to improve CTCs capture
efﬁciency but also to increase prognostic and predictive informa-
tion [7].
At the metastatic site, a reversion to an epithelial morphology,
also known as mesenchymal-to-epithelial transition (MET), has
been postulated and proposed to be essential for disseminated
tumor cells to re-enter a proliferative state and give rise to
macrometastatic nodules [10]. The mechanisms underlying this
process are still poorly understood. However, an explanation of this
process was proposed by Brabletz and involves the differentiated
vs undifferentiated status of primary tumors. The dynamic EMT-
MET interconversion is an important determinant of metastases
characterised by differentiated cells [11]. In this model, cancer cells
in primary tumors acquire EMT to increase their metastatic
potential, maintain the EMT status in circulation, and undergo a
MET at the secondary metastatic sites to promote metastatic
colonization. In contrast to the EMT-MET model, undifferentiated
metastases derived from primary tumors with intrinsic genetic
alterations are in a permanent EMT state and only a weak
redifferentiation is necessary to support their growth [11].
When considering the contribution of EMT in cancer progres-
sion, it is important to address its role during the ﬁrst steps of
cancer initiation. Although EMT may be principally ascribed to
later stages of carcinoma progression, evidences that EMT may
occur earlier and be detectable in precancerous lesions are
reported. In a mouse model of pancreatic cancer, EMT was
identiﬁed in premalignant lesions and cells with mesenchymal
features were present in the circulation of mice prior to the
development of a detectable malignancy [12].
The EMT process has been characterized in different cancer
types including breast [13], lung [14], ovarian [15], prostate [16],
and liver [17] cancers. The mechanisms by which an epithelial cell
is able to acquire a mesenchymal phenotype include the
diminished expression of cell–cell adhesion components, elevated
expression of proteins involved in cytoskeleton remodeling, and
increased motility (Fig. 1). Such mechanisms have important
implication for the identiﬁcation of a set of EMT markers that can
be clinically useful to characterize the process. Depending of theirspeciﬁc role, EMT driving factors can be involved in transcriptional
regulation, maintenance of epithelial integrity and metabolism.
2. Factors driving EMT activation
EMT results from the coordinated regulation of transcriptional,
post-transcriptional, translational and post-translational events.
At the transcriptional level, EMT is regulated by several transcrip-
tion factors including zinc-ﬁnger proteins (SNAI1/2 and ZEB1/2)
and basic helix-loop-helix proteins (TWIST1/2). Overexpression of
these factors has been shown to be sufﬁcient to act as a trigger of
the EMT program, increasing cell migration and invasiveness of
tumor cells [18].
In addition to the contribution of this transcriptional program,
small-non coding RNAs or microRNAs (miRNA or miR) have been
found to play a critical role in EMT regulation [19]. MiRNAs can
either promote or repressing the EMT program, depending on the
different cell contexts. MiR-200 family acts by targeting the EMT
factors Zeb1 and Zeb2, thus preventing E-cadherin down-regula-
tion [20,21]. However, members of this family are also required to
promote EMT and metastatization [22]. MiRNAs can cooperate
with different EMT-controlling signaling networks. In ovarian
cancer, miR-181a can modulate tumor growth factor-b (TGF-b)
signaling, increasing cell survival, drug resistance, and tumor
dissemination [23]. In breast cancer, ectopic overexpression of
miR-374a promoted EMT and metastasis both in vitro and in vivo by
targeting several negative regulators of the Wnt/b-catenin
signaling cascade [24]. Taken together, miRNAs may regulate
EMT working in close collaboration with transcriptional factors or
reinforcing EMT signaling network.
Tumor microenvironment including immune cells, tumor
stroma, and extracellular matrix can participate in the regulation
of EMT through a direct cell contact or by secreting signaling
factors such as TGF-b, epidermal growth factor (EGF) or platelet-
derived growth factor (PDGF), and hormones [25]. Cancer-
associated ﬁbroblasts (CAFs) can promote EMT, by releasing
CXCL12 or by activating speciﬁc collagen receptors that regulate
the stability of EMT transcription factors, respectively [26,27]. The
crucial role of the microenvironment during EMT is also supported
by the observation that circulating tumor cells can undergo EMT in
response to a physical interaction with platelets. Platelet-derived
TGF-b triggers EMT through the synergistic activation of TGF-b
and nuclear factor-kB (NF-kB) pathways [28].
TGF-b pathway promotes EMT and also enhances the migratory
and invasive properties of cancer cells. The latter events are
transiently active only in a small population of cells throughout the
tumor where activation of TGF-b signaling drives the expression of
genes that promote single cell motility [29]. Proteomic studies
provided a systemic view of TGF-b action. The process is regulated
via the activation of ECM-receptor interaction, focal adhesion, and
actin cytoskeleton proteins and the down-regulation of proteins
related to cell cycle inhibition, nucleic acid metabolism, transcrip-
tion, and regulation of DNA replication and repair. Important
effectors of these modiﬁcations include the transcriptional
regulators SMAD2, SMAD3, SNAIL2, SMAD7, and c-MYC [30].
EMT is regulated by the interplay of different signaling
networks, with multiple points of regulation, feedback and
cross-talk. Canonical EMT pathways include Ras/MAPK, PI3 K/
Akt/GSK, and Wnt/b-catenin. ERK is critical for EMT induction by
the hepatocyte growth factor (HGF) [31], TGF-b [32], or EGF [33].
In melanoma cell lines, increased Twist1 mRNA/protein expression
was shown to be dependent on the ERK signaling thus promoting
invasion, and matrix metalloproteinase-1 expression [34]. Activa-
tion of the PI3K and MAPK pathways can also regulate EMT by the
suppression of GSK-3b activity and stabilization of Snail. GSK, by
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degradation and subcellular localization [35].
The Akt family of kinases, comprising Akt-1, Akt-2 and Akt-3, is
a major effector of tumor growth and metastasis. Although the
signaling through Akt is essential to promote EMT, the functional
role and relative contribution of the three different isoforms is still
controversial [36]. In breast cancer samples, the ratio of Akt-1 to
Akt-2 and the abundance of miR-200 and of the mRNA encoding E-
cadherin revealed that the miR-200-E-cadherin axis is under the
control of Akt pathway. The comparison of cells reconstituted with
Akt-1, or Akt-2 demonstrated that miR-200 family expression
appears to depend on the balance between Akt-1 and Akt-2. Akt-
1 may regulate Akt2 or it may interfere with the Akt-2-mediated
decrease in miR-200 abundance downstream of Akt-2. Akt-
1 knockdown, but not down-regulation of Akt-2 or of Akt-1 plus
Akt-2, contributes to the activation of EMT induced by TGF-b by
decreasing the abundance of the miR-200 family [36]. Activation of
Akt drives the acquisition of a mesenchymal phenotype in
squamous cell carcinoma lines promoting tissue invasion and
metastasis [37]. Hepatocellular carcinoma cells exposure to
hypoxic conditions increased HIF-1a expression and induced
EMT through a pathway that involves PI3K/Akt [38]. In vivo, high
levels of Akt were found to correlate with high levels of
Twist1 Ser42 phosphorylation with subsequent decrease of
p53 levels and the inhibition of cell cycle arrest and apoptosis
[39]. Akt can also regulate EMT through NF-kB. Akt induces NF-kB
activity, its nuclear translocation and Snail activation with the
consequent repression of the CDH1 gene encoding E-cadherin [40].
Connections between Wnt signaling and EMT is supported by
several studies. In the canonical WNT signaling, the binding ofFig. 1. Cellular modiﬁcations associated with EMT program. After the activation of the EM
cadherin and Cytokeratins, and turn on mesenchymal markers, including N-cadherin and
into epithelial structures by mesenchymal-epithelial transition. Depending on the tissu
show some epithelial and mesenchymal properties; this can be considered as a partialWNT ligands to the Frizzled family of protein receptors results in
the inhibition of GSK3b activity leading to stabilization of Snail and
Slug expression [41,42]. During EMT, Wnt signaling is implicated in
the reprogramming and maintenance of a cancer stem cell (CSC)
state. This is obtained through the association of Twist1 with Wnt
signaling-related molecules. In particular, EMT activation in tumor
cells induces a switch from the b-catenin/E-cadherin/
Sox15 complex to the b-catenin/Twist1/TCF4 complex enhancing
the transcriptional activity of this group of proteins including the
binding to cancer stem cell genes related promoters. Immunohis-
tochemical analysis of lung cancer samples correlated the speciﬁc
protein signature identiﬁed in vitro (nuclear b-cateninHigh/nuclear
Twist1High/E-cadherinLow/Sox15Low/CD133High) with clinical fea-
tures including tumor progression and metastasis. These data
indicated the potential role of these proteins as predictors for poor
overall patient survival [43].
3. Immune response and EMT
A link between EMT and immunoediting was described and
several mechanisms proposed. Tumor cells that evade immu-
noediting often activate EMT signaling pathways such as BRAF-
MAPK, STAT3, and Wnt/b-catenin which trigger multiple
immunosuppressive cascades that result in the production of
immunosuppressive molecules (e.g., TGF-b, IL-10, IL-6, VEGF, and
CCL2) and induction of immunosuppressive immune cells (e.g.,
regulatory T cells, tolerogenic dendritic cells, and myeloid-derived
suppressor cells) [44–46]. Moreover, during EMT, tumor cells
evade the immuno-recognition through the down-regulation of
immune receptor ligands that directly stimulate immune cells. InT program epithelial cells switch off the expression of epithelial markers, such as E-
 Fibronectin. After metastatic dissemination mesenchymal cells can redifferentiate
e and signaling context, epithelial cells may lose only some characteristics or may
 EMT.
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group 2 member D (NKG2D) expressed in natural killer (NK) and T
cells which is involve to recognize malignant cells is under the
control of an immunological checkpoint that relies on NKG2D-
mediated immune responses in EMT [47]. We demonstrated the
down-regulation of Human leukocyte antigen class I antigens
(HLA-I) in serous ovarian cancer, which is essential in immune
response by presenting antigenic peptides to cytotoxic T
lymphocytes. This is done by cleavage of the immunoproteasome
11S [48]. Cleavage of PSME1 (proteasome activator complex
subunit 1, 11S regulator complex [syn: PA28 alpha]), an antigen
processing machinery, into the Reg-alpha fragment could lead to
default self-antigen presentation [48,49]. Our data describe a high
expression level of PA28 in early and late stages ovarian
carcinomas, and proposed a role for this protein as a marker for
monitoring patient response during therapy [49]. Its alteration by
cleavage in ovarian carcinomas may be a mechanism to evade
immune recognition. Similar hypothesis has already been
proposed in the case of APM chaperones such as TAP, LMP2,
LMP10, and tapasin in colon carcinoma, small cell lung carcinoma,
and pancreatic carcinoma cell lines. In fact, IFN-ã treatment of
these carcinoma cell lines corrects the TAP, LMP, and tapasin
deﬁciencies and enhances PA28<LMP7, calnexin and calreticulin
expression, which is accompanied by increased levels of MHC class
1 antigens. Recently, the PA28 fragment was detected in a MALDI
MSI multicentric study and correlated to stroma activation in
breast cancer samples [50].
There are data to support the role of soluble molecules
expressed or secreted in the tumor microenvironment in the
regulation of EMT and immunoediting. Recent data suggest that
TGF-b and EGF play a role in regulating HLA-I. The treatment of
prostate cancer cells with TGF-b and EGF induced and EMT
program and signiﬁcantly decreased HLA-I expression. This
attenuated the cytotoxic T cell mediated lysis of tumor cells
through a pathway that involve the up-regulation of Snail [51].
Taken together, it is clear that in EMT hallmarks the immune
response take a major place as a therapeutic target.
4. Clinical relevance of genes/proteins associated with EMT
In support to the relevance of EMT, histological analysis of
tumor samples suggested that EMT occurs in vivo promoting
cancer progression and chemoresistance.
Loss of cell polarity is a main event in several epithelial tumor
types, as loss of the junctions mediating tissue architecture could
contribute to the formation of tumor masses in vivo [52], or
promote the expansion of pre-neoplastic cell [53]. One fundamen-
tal event of EMT is the decrease of E-cadherin expression, an
adherent junction protein implicated in cell–cell adhesion of
epithelial tissues. There are multiple mechanisms by which E-
cadherin inﬂuences tumor progression, including inhibition of EGF
receptor signaling and maintenance of cell–cell adhesion and
epithelial cell polarity [54]. Reduced E-cadherin expression is often
associated with the release of b-catenin into the cytosol and
potentially into the nucleus [54]. Immunohistochemical analysis of
breast cancer samples revealed that this association is a
characteristic of tumors of triple-negative and basal-like pheno-
type [55].
Several studies have correlated the down-regulation of E-
cadherin with clinicopathological parameters of several human
tumor types. In a cohort of squamous cell lung carcinoma patients,
high E-cadherin expression can be a positive indicator for overall
survival (OS) and disease-free survival (DFS) [56]. Increased
cytoplasmic ALCAM/E-cadherin loss was found to represent the
most signiﬁcant adverse prognostic factors for oral squamous cell
carcinoma (OSCC) patients [57].A meta-analysis of 24 studies and 2961 cases suggested that E-
cadherin expression is signiﬁcantly associated with poorer
differentiation degree in esophageal cancer [58]. Moreover,
abnormal E-cadherin expression emerged as a strong independent
prognostic factor for overall survival of gastric cancer patients [59].
Stable loss of E-cadherin can occur through different molecular
mechanisms, including promoter hypermethylation and transcrip-
tional control. The transcriptional repressors of E-cadherin
expression, Snail, Slug and Twist, are involved in the activation
of EMT by binding to E-box elements in the E-cadherin promoter.
These factors can regulate EMT in vitro through the repression of E-
cadherin, the up-regulation of mesenchymal markers, and the
acquisition of stem cell properties [18]. Knockdown of these
transcription factors restores the expression of E-cadherin and
induces an epithelial phenotype [60]. Although these EMT
regulators are thought to function in a redundant manner, several
studies reported unique functions suggesting a differential
participation in the EMT process [61] with a precise spatial and
temporal regulation [61,64]. In breast cancer patients, Snail levels
in the primary tumor predicted for metastasis, while Twist levels
and the Twist/Snail ratio in bone marrow micrometastatic tumor
cells were found to be highly predictive for distant relapses [62]. In
a cohort of patients with invasive ductal carcinoma, Snail
expression correlated with b-catenin cytoplasmic and nuclear
levels, while Slug correlated with N-cadherin and vimentin protein
expression [63]. In melanoma cells, the expression of EMT factors is
under the control of oncogenic signaling pathways. During
melanomagenesis Snail2 and Zeb2 behave as onco-suppressive
proteins in the melanocytic differentiation program, whereas, in
response to MEK-ERK pathway activation, Zeb1 and Twist1 are up-
regulated promoting dedifferentiation and neoplastic transforma-
tion of melanocytes [64].
Snail, Slug and Twist are expressed in the nuclear and
cytoplasmic fraction of tumor samples, and correlated with
advanced stage, and poor survival in several cancer types
[65,66]. Moreover, there is some evidence of a positive staining
of these transcription factors in tumor microenvironment of tumor
samples with a worse outcome [67].
High expression of nuclear Snail predicts poor survival in
nasopharyngeal carcinoma and basal-like breast cancer [65,66].
Twist over-expression was observed in patients with head and
neck squamous cell carcinoma, clear cell carcinoma of the ovary,
advanced oral squamous cell carcinoma, colorectal carcinoma,
breast carcinoma and associated with aggressive tumor properties
and poor survival [68–71]. The prognosis of patients with Twist
and Snail co-expression is worse in tumor samples compared with
samples where only one marker is expressed, supporting the
hypothesis that these two transcription factors may cooperate to
promote EMT [72].
N-cadherin up-regulation frequently follows E-cadherin down-
regulation with a concomitant increase of cell motility and
migration [73]. N-cadherin over-expression stimulates mammary
tumor metastasis in the MMTV-NeuNT mouse model, and induces
up-regulation of FGFR expression and phosphorylation, and of
Snail and Slug expression in a FGFR-dependent manner [74]. N-
cadherin expression is positively correlated with clinical param-
eters in several cancer types. In lung cancer tissues, overexpression
of N-cadherin is associated with advanced TNM stage, poor
differentiation and reduced overall survival. Moreover, a signiﬁ-
cant correlation was found between Twist and N-cadherin
expression by Spearman correlation analysis [75]. Moreover, N-
cadherin expression was found to correlate with superﬁcial
urothelial tumor progression and with poor histological differen-
tiation of oral squamous cell carcinomas [76,77].
Vimentin is the major intermediate ﬁlament protein of
mesenchymal/stromal cells, including ﬁbroblasts, endothelial cells
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approaches reported altered expression levels for vimentin in
numerous cancer types, correlating its overexpression with the
aggressive behavior and metastatic potential of these tumors [79–
86]. In epithelial tumors, expression of vimentin alone or in
combination with other mesenchymal markers is a useful
predictor of cancer progression, chemoresistance, high histological
grade, and in general associated with poor prognosis. Vimentin
immunoreactivity has been observed in both stromal and tumor
cells where it is expressed at the invasive front [85].
High expression of vimentin was observed in triple-negative
breast cancer compared with other breast tumour subtypes, and
correlated with younger age, high nuclear grade, high
Ki67 expression, and poor prognosis in terms of both recur-
rence-free survival and overall survival [87,88]. Vimentin is a
predictive biomarker in patients with non-small cell lung cancer
treated with Erlotinib as second- or third-line therapy [89], and a
negative indicator for overall survival in squamous cell lung
carcinoma patients [56].
4.1. Clinical signiﬁcance of combined detection of FDA serum tumor
markers and EMT markers
The potential uses of cancer markers are for screening,
diagnosis, prognosis, prediction of response to therapy, monitoring
of patients with diagnosed disease. Since EMT markers have
demonstrated clinical value in detection and monitoring of a
disease, their expression may improve the sensibility and
speciﬁcity of most traditionally used clinical markers. Moreover,
despite their prevalent tissue-based location, EMT markers can
also be found in other biological ﬂuids, including serum, increasing
their potential clinical utility. So far, only few EMT markers have
been proposed in correlation with US Food and Drug Administra-
tion (FDA)-approved biomarkers.
Alpha-fetoprotein (AFP) is an indicator of several malignant and
chronic conditions, including hepatocellular carcinoma (HCC) [90].
The expression of AFP in HCC models is regulated by the miR122
[91], which is associated with EMT and spontaneous HCC
formation [92]. Reduced expression of miR122 in HCC cells
contributes to elevated AFP expression through a pathway
involving CUX1/miR214/ZBTB20; this evidence suggests that
serum AFP levels in HCC patients may be a surrogate marker for
deregulated intracellular miR122-dependent signaling pathways
in HCC tissues.
Vimentin is an EMT markers consistently over-expressed in
HCCs compared to cirrhotic and normal liver tissues [93]. This
over-abundance was more marked in smaller carcinomas (2 cm).
In the serum of HCC patients, vimentin expression as detected by
ELISA described a signiﬁcant difference between non-neoplastic
controls and HCCs of all sizes and a speciﬁcity of 87.5% (95% CI:
76.85–94.45%) in separating non-neoplastic subjects from those
with HCCs of small size. Importantly, vimentin was proposed as a
better marker compared with the conventional serum AFP for
detecting small tumors and that when combined with AFP, this
detection sensitivity and speciﬁcity can be considerably enhanced.
Mucins are a large family of transmembrane glycoproteins, and
are frequently over-expressed and aberrantly glycosylated in
cancer. Mucins are secreted from and/or localized to the apical
borders of normal epithelial cell sheets. Over-expression of MUC1,
MUC4, and MUC16 has diagnostic and prognostic signiﬁcance in
different cancer types [94].
MUC16 is a high molecular weight membrane associated-
mucin, which is over-expressed in advanced serous epithelial
ovarian cancers [95]. CA125 is a marker that allows the detection of
circulating MUC16 antigen, which is increased in approximately
80% of all epithelial ovarian cancers (EOC) and in only 50% of stage IEOC and associated with a signiﬁcantly longer progression-free
survival and overall survival [96]. CA125 serum levels directly
correlate with the levels of protein production in tumor cells
suggesting that the up-regulation of this protein at the tissue level
may have a role in promoting cancer progression and recurrence.
Knockdown of MUC16 decreased the ability of tumor cells to form
colony in soft agar and prevented the formation of subcutaneous
tumors in nude mice. In contrast, tumor cells with an ectopic
expression of MUC16 showed a decrease of E-cadherin and a gain
of N-cadherin and vimentin expression together with an enhanced
tumorigenic phenotype [97]. Although this data suggests a
functional role of MUC16 in regulating EMT, results from another
study report an inverse correlation between CA125 serum levels
and the expression of mesenchymal markers at tissue level. The
study of Tothill et al. described that preoperative serum
CA125 levels are lower in ovarian cancer tissues with a
mesenchymal gene signature compared with tissues characterized
by a different genomic proﬁle [98]. These data suggest that
MUC16 expression may be needed to promote the onset of EMT but
not to maintain a mesenchymal phenotype.
MUC1 is approved as a biomarker for breast cancer in
combination with diagnostic imaging, patient history, and physical
examination during active cancer therapy to monitor metastatis
[99]. Two serum assays, CA15.3 and CA27.29, were approved by the
FDA for the detection of secreted MUC1 in breast cancer patients.
Moreover, MUC1 is aberrantly over-expressed in greater than 95%
of metastatic pancreatic cancer and associated with poor prognosis
[100]. Over-expression of MUC1 can induce EMT by b-catenin-
MUC1 interaction and translocation to the nucleus, leading to
activation of Snail and Slug [101]. Moreover, MUC1 stimulates the
over-expression of Zeb1 and the down-regulation of miR-200c,
with consequent induction of EMT [102].
In 1965, the oncofetal antigen carcinoembryonic antigen (CEA)
was found for the ﬁrst time in extracts of colonic adenocarcinomas
[103]. CEA belongs to a large family of carcinoembryonic antigen
cell adhesion molecules (CEACAMs) proteins that mediate
homophilic and heterophilic cellular interactions [104]. The
utilization of CEA in clinical applications is mainly aimed at the
management of gastrointestinal malignancies, especially colorec-
tal carcinomas. It is also detected in various epithelial tumors such
as lung, small cell lung cancer, pancreas, gallbladder, urinary
bladder, mucinous ovarian, and endometrium [105]. In a cohort of
99 pancreatic tumor samples, CEACAM6 (CD66c) expression was
correlated with clinicopathological characteristics including tumor
differentiation and lymph node status, and inversely correlated
with E-cadherin expression. Silencing of CEACAM6 in pancreatic
CFPAC-1 cells led to a transition from mesenchymal to epithelial
morphology with a concomitant up-regulation of E-cadherin and
down-regulation of vimentin [106]. In breast cancer samples, the
combined analysis of CEA and E-cadherin expression showed a
3.6 times higher risk of relapse for patients with elevated
expression of CEA, regardless of E-cadherin expression, compared
with patients with below-median CEA and above-median E-
cadherin tumour expression [107].
5. EMT markers in biological ﬂuids
Despite extensive investigations, there are no currently
approved applications for canonical EMT markers in the clinical
setting. This is in contrast with the importance of EMT in the
context of cancer biology and with their correlation with a series of
clinical variables as supported by recent experimental studies.
There are multiple reasons why EMT markers have not gone
through the clinic and they are to some extent related to the
dynamic nature of the process. As described above, primary
tumors are characterized by the expression of EMT markers whose
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Hence, only a particular marker may be expressed at any time point
with the unavoidable consequence that tissue slices should be
probed with several different antibodies, which may lead to an
increase of healthcare cost.
The detection of tumor markers in the blood is a highly active
area of research that will extend the use of EMT markers in the
clinic providing a shift from the classical histological diagnosis
based on the anatomical site. A proteomic signature of breast
cancer biomarkers released in proximal ﬂuids was assessed by
liquid chromatography mass spectrometry (LC–MS/MS). Authors
analysed the proximal ﬂuids of seven breast cancer cell lines with
different EMT features, and identiﬁed a group of proteins whose
expression varied signiﬁcantly among cell models [108]. A set of
three markers, cathepsin D, fructose 1,6-bisphosphate aldolase,
and keratin 19, was required to categorize breast models as
HER2 positive, HER2 negative and hormone receptor positive, and
triple negative. Other authors investigated by 2DE-DIGE and LC–
MS/MS the secretome of MDCK and Ras transformed MDCK cells
[109]. Ras transformed cells exhibit typical EMT features including
an increased migratory capacity and an up-regulation of extracel-
lular proteases and factors promoting migration. Among the
proteins identiﬁed, kallikrein 6 (KLK6) was six folds up-regulated
in the secretome of Ras transformed MDCK cells. KLK6 may
represent a promising biomarker, because this protein belongs to a
family of serine proteases, which includes also the clinical
biomarker KLK3 (known as prostate-speciﬁc antigen, PSA).
However, its role in the EMT scenario is not totally clear, because
a recent study unrevealed an inhibitory function of KLK6 on tumor
cell proliferation and mobility and an inverse correlation to EMT
[110].
6. Using proteomics to dissect EMT complexity
A differential proteomic analysis was performed to investigate
the proteome modiﬁcations after the induction or knockdown of
EMT markers, or to compare cell and tissue models with different
EMT features. Other approaches have been used to expand the
information about EMT markers including immunoprecipitation of
protein complexes followed by MS/MS.
Advances in MS-based proteomics provided a systems view of
functional networks modiﬁed after EMT induction [111]. To
address this issue and to enable the study of global proteome
modiﬁcations, different fractionation methods were used. This
approach includes the analysis of membrane, cytosol, and nuclear
proteins, and the isolation of phosphopeptides that were enriched
by direct afﬁnity chromatography. This strategy was evaluated in
an inducible model of EMT that was obtained using tumor cell lines
in which the expression of Snail and Zeb1 was under the control of
a doxycycline inducible promoter. Cells were treated with TGF-b
for one week, and lysed to fractionate cellular speciﬁc components
that were analysed by LC–MS/MS. High-throughput proteomics
revealed modiﬁcations in a wide range of cellular networks and
alterations in the expression of cell–cell junctional proteins, an
increased production of proteases, an up-regulation of proin-
ﬂammatory cytokines, and a reduced need of metabolic pathways
required for macromolecular biosynthesis. These modiﬁcations
correlate with the modulation of speciﬁc transcription nodes
including NFkB2/RelA, ATF3/ATF2, Myc, FOXA1 and 2, ETS1,
NFE2L2/L3, MEF2C, Snail/Slug, and Zeb1 and 2.
As discussed above, several signaling pathways can induce EMT
and many EMT inducers have been identiﬁed including HGF.
Shotgun proteomics combined with SILAC, for the quantitative
comparison of proteomic differences, was applied to identify HGF-
induced expression changes in MDCK cells. Six protein clusters
modiﬁed their expression in a time-dependent manner afterdifferent time points of stimulation. In particular, the expression of
proteins that regulate cell cycle, cell migration, integrin signaling,
ubiquitination, and transcription increased over 24 h of HGF
exposure, in contrast, metabolic enzymes, pro-apoptotic, and
transcriptional suppressors decreased over the same period.
Moreover, members of HIPPO/MST2 and ISG15 pathways were
modiﬁed after HGF-treatment at the protein level by ubiquitin
ligases. Modulation of these pathways seems to have a major role
in regulating cell scattering and morphology [112].
Cells undergoing EMT acquire resistance to anticancer agents
and contribute in vivo to the generation of chemoresistant
metastasis [113,114]. In pancreatic adenocarcinoma, intrinsic
gemcitabine-resistant and -sensitive human cell lines were
compared by a label free quantiﬁcation strategy to identify an
EMT-proteomic signature associated with the resistant phenotype
[115]. The list of identiﬁed proteins includes the EMT markers
ANPEP, ALCAM, DSG3, DSG2, KRT14, KRT19, KRT8, CLDN1, VIM,
CDH1, SDC1, CD44, ITGB1, NT5E, and DSP, suggesting that the
acquisition of a mesenchymal phenotype is involved in gemcita-
bine resistance. As many of these proteins are closely associated
with cytoskeletal reorganization, the acquisition of a more
aggressive and invasive phenotype may be important in conferring
drug resistance against gemcitabine.
Breast cancer models have been widely used to study EMT.
Based on the established molecular classiﬁcation, breast tumors
can be divided into several subtypes with speciﬁc epithelial and
mesenchymal features. In this classiﬁcation, triple-negative breast
cancers (TNBC), represent a speciﬁc group enriched for the
expression of mesenchymal markers. Compared to HER2 cancer
samples, TNBC display a proteomic proﬁle characterised by the
over-expression of breast cancer stem cells markers, such as
ALDH1A1, and drug-resistance proteins including Hsp70, Periostin
precursor, RhoA, Actinin a4, and Annexin1 [116]. Annexins belong
to a family of calcium/phospholipids-binding and actin regulatory
proteins, and play an important role in the regulation of EMT. In
mesenchymal breast cancer cells, Annexin1 was found differen-
tially expressed at protein and mRNA level [117], and identiﬁed as a
marker for breast cancer outcome prediction and treatment
response [118]. Recently, the deeper proteomic classiﬁcation
performed by Lawrence and colleagues highlighted the remarkable
differences between TNBC and luminal tumors. This result
supported the metastatic potential of mesenchymal tumors, which
express high level of signaling proteins associated with metastasis,
including ECM receptor interaction, cell adhesion, and angiogene-
sis [119].
A hallmark of EMT is the down-regulation of cell–cell junctions,
including adherens junctions. In our group we used a proteomic
approach to identify proteins modiﬁed after the knockdown of E-
cadherin in breast cancer cells. Experimental data were obtained
from two different models, MCF-7 and MDA-415 cells stably
infected with a lentivirus for the expression of speciﬁc E-cadherin
shRNAs. Bioinformatics analysis of this protein dataset revealed
that different protein networks were modiﬁed after E-cadherin
knockdown, including cell invasion, viability, survival, and
metabolism [120]. This expands the role of E-cadherin to a
possible regulation of other pathways not strictly related to cell
adhesion, and highlights the complexity of the E-cadherin
interactome. Immunoprecipation experiments using MS provided
a sensitive way of characterising speciﬁc molecules that directly
are inﬂuenced by E-cadherin. One of these methodologies relies on
the application of biotin-streptavidin afﬁnity chromatography and
LC–MS/MS to identify proteins associated with an engineered form
of E-cadherin, which expresses a biotin ligase to biotinylate
proteins based on its proximity [121]. Biotinylated proteins were
then isolated by streptavidin afﬁnity chromatography, digested
into peptides, and analyzed by high-resolution MS. In the
Table 1
Proteomic studies applied to study the EMT complexity.






Analysis of the proteomic and phosphoproteomic
changes of cultured human keratinocytes undergoing
EMT in response to stimulation with TGF-b. Authors
quantiﬁed signiﬁcant changes in 2079 proteins and
2892 phosphorylation sites regulated by TGF-b
Authors performed a networks and pathways analysis
of TGF-b regulated proteins which revealed signiﬁcant
differences in the abundance of proteins associated
with EMT and cell proliferation. A set of upstream






Authors identiﬁed and characterized the most
abundant secreted proteins from a panel of cancer
human cell lines: HER2 positive, HER2 negative and
hormone receptor positive and triple negative
(HER2, ER, PR)
Bioinformatics analysis classiﬁed HER2 positive,
HER2 negative and triple negative models based on
the expression of only two proteins, muscle fructose
1,6-bisphosphate aldolase and keratin 19
[108]
2-D DIGE and LC–MS/
MS
2-DE image analysis
software and mRNA and
western blot validation
Authors compared the secretome of MDCK cells that
undergo EMT following transformation with
oncogenic Ras
DIGE analysis identiﬁed 47 proteins differentially
regulated in MDCK cells after Ras-induced EMT.
Proteins involved in cell migration and matrix
degradation were enriched in this network
[109]
LC–MS/MS iTRAQ EMT was induced in a tumor cell model stably
transfected with doxycycline-inducible Zeb1 or Snail
cDNAs or after the exposed to exogenous TGF-b
Proteomic changes were investigated after cellular
fractionation of membrane, nuclear, and cytosolic
proteins. Phosphopeptides were also isolated by
directed afﬁnity chromatography
Four functional groups of proteins were modiﬁed after
EMT activation: cell adhesion and migration,
metabolism, transcription nodes and proliferation/
survival networks
[111]
LC–MS/MS SILAC Authors performed a quantitative proteomic analysis
of MDCK cells treated with HGF at different time
points
After HGF exposure, MDCK cells expressed higher
levels of proteins associated with the ubiquitination
machinery, whereas expression of proteins regulating
apoptotic pathways was suppressed. Hippo/MST2 and






Authors performed a comparative proteomic analysis
of pancreatic cancer cell lines with a different
sensitivity to gemcitabine
Bioinformatics analysis identiﬁed 13 EMT-related
proteins that were closely associated with drug
resistance including CAV1, IQGAP1, ITGB4, ITGA6,






Authors performed a comparative proteomic proﬁling
of HER2 positive and triple negative breast cancer
tissues
Galectin-3-binding protein and ALDH1A1 were found
preferentially elevated in TNBC, whereas CK19,
transferrin, transketolase, and thymosin b4 and
b10 were elevated in HER2-positive cancers
[116]
2-DE and TOF/TOF 2-DE image analysis
software and mRNA and
western blot validation
In this paper authors performed a comparative
proteomic analysis of two breast cancer cell lines with
epithelial and mesenchymal features
28 proteins were identiﬁed as signiﬁcantly up- and
down-regulated. Proteins that were differentially
expressed by these cell lines were enriched for
metabolic, mobility, and signaling functions
[117]
LC–MS/MS iBAQ approach This paper is a large-scale proteomic characterization
of triple negative breast cancer cell lines and tissues
using MS. Results of this study are freely available at
the website (https://zucchini.gs.washington.edu/
BreastCancerProteome/)
PCA analysis classiﬁed tumor samples into different
groups. Luminal-like cells expressed higher levels of
pathways associated with proliferation, such as cell
cycle, growth factor signaling, metabolism, and DNA
damage repair mechanisms. TNBC cell types,
expressed higher levels of pathways associated with
metastasis, such as ECM-receptor interaction, cell
adhesion, and angiogenesis
[119]
2-DE and TOF/TOF 2-DE image analysis
software and western
blot validation
Proteomic analysis of breast cancer cell lines after
shRNA knockdown of E-cadherin
81 spots differentially expressed between scramble
and shEcad cells, 54 proteins identiﬁed by MS/MS.
Proteins involved in the regulation of actin





iBAQ approach Authors used immunoprecipitation and LC–MS/MS to
identify 561 E-cadherin interactome components
More than 50% of the 561 identiﬁed proteins belong to
six main groups including adaptor proteins,
transmembrane proteins, guanosine triphosphatase
(GTPase) regulators, kinases and phosphatases, actin
dynamics regulators, and cytoskeleton structural and
motor proteins
[121]
V. Daniele et al. / EuPA Open Proteomics 10 (2016) 31–41 37immunoprecitated of E-cadherin, 561 proteins were identiﬁed and
classiﬁed in different functional categories based on their gene
ontology. The largest group was that of adaptor proteins, the
remaining categories included transmembrane proteins and
proteins involved in transcription, translation, trafﬁcking, proteol-
ysis and metabolism.
7. Conclusions
Data discussed in the above sections describe the biological
complexity of EMT and report the role of high-throughputtechnologies to provide insight into this complexity (Table 1).
Although the molecular details that underlie the process still need
to be completely clariﬁed, these results highlight how EMT takes
advantage by the activation of different cellular pathways that
work in coordination to sustain cells adaptation to a different
molecular program. Besides the role of classical EMT markers such
as cell–cell adhesions proteins and transcription factors, other
potential markers were identiﬁed by proteomics. Considering the
patient-to-patient biological variation, large multi-center studies
are required to prove the validity of these molecules as clinical
biomarkers. Moreover, extensive experimental evidence indicates
38 V. Daniele et al. / EuPA Open Proteomics 10 (2016) 31–41the need to shift the focus from a single or few biomarkers towards
large panels of EMT markers that can better describe the molecular
dynamism of a tumor. In this direction, the usefulness of EMT
markers alone or in combinations still remains to be determined,
although initial studies using with multi-marker combinations are
promising [122]. To achieve this goal, proteomics technologies can
now support the screening of a large set of samples with great
sensitivity also in combination with targeted data acquisition
strategy. An example of this approach was recently carried out for
the discovery and validation of breast cancer biomarkers. In this
work, a list of N-glycosylated proteins was obtained from breast
cancer samples with different clinical features. Then, a list of
putative biomarkers was selected and quantiﬁed by LC-SRM
(single reaction monitoring) leading to the validation of 10 proteins
differentially expressed in tumor samples [123]. More recently,
analyses performed on quadrupole-orbitrap mass spectrometers
operated in hyper reaction monitoring (HRM) enables compre-
hensive recording of a large number of peptide ions with high
precision and reproducibility bypassing the drawbacks associated
with SRM [124]. The approach was used to investigate the effect of
acetaminophen (APAP) on the proteome of liver microtissues
generating a spectral library of more than 22.454 peptides [125].
This further expands the role of proteomics in the clinical
investigation and validation of biomarkers, with new opportu-
nities also in the ﬁeld of EMT.
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